文献速递甲状腺疾病

BRAFV600E抑制联合多靶点酪氨酸激酶抑制剂阿昔替尼在BRAFV600E突变未分化甲状腺癌中显示叠加抗癌活性

Combination BRAFV600E Inhibition with the Multitargeting Tyrosine Kinase Inhibitor Axitinib Shows Additive Anticancer Activity in BRAFV600E-Mutant Anaplastic Thyroid Cancer.
PubMed 文献 · Thyroid · 2023-10-03

研究在BRAFV600E突变及野生型未分化甲状腺癌(ATC)的体外和体内模型中,评估BRAFV600E抑制剂(达拉非尼、PLX4720)与多靶点酪氨酸激酶抑制剂阿昔替尼单用及联用的效果。结果显示联用对BRAFV600E突变ATC细胞增殖呈叠加抑制,显著抑制侵袭和迁移(p < 0.001),并在原位ATC模型中显著抑制肿瘤生长、改善生存。作者认为该联合方案可能对当前标准治疗(BRAF联合MEK抑制)难治的BRAFV600E突变ATC有临床价值。

要点

  • 阿昔替尼与BRAFV600E抑制剂联用在BRAFV600E突变ATC细胞中呈叠加抑制增殖效应。
  • 联用显著抑制细胞侵袭和迁移(p < 0.001),达拉非尼和PLX4720使细胞阻滞于G0/G1期。
  • 原位ATC模型中联用显著抑制肿瘤生长并改善生存。

核心结论

  • 阿昔替尼与BRAFV600E抑制的新联合在BRAFV600E突变ATC的体外和体内模型中增强抗癌活性。
  • 该联合可能对当前标准治疗即BRAF联合MEK抑制难治的BRAFV600E突变ATC有临床价值。

研究设计与样本

  • 在BRAFV600E突变和野生型ATC的体外与体内模型中评估BRAFV600E抑制剂及阿昔替尼单用与联用的效果。
  • BRAFV600E突变存在于45%的ATC患者中。

主要发现

  • 基于Chou-Talalay算法,阿昔替尼与BRAFV600E抑制剂(达拉非尼和PLX4720)联用在BRAFV600E突变ATC细胞系中对抑制细胞增殖显示叠加效应。
  • 该联合与对照相比显著抑制细胞侵袭和迁移(p < 0.001)。
  • 达拉非尼和PLX4720使ATC细胞阻滞于G0/G1期。
  • 阿昔替尼通过降低极光激酶B(Thr232)和组蛋白H3(Ser10)蛋白磷酸化并上调c-JUN信号通路使ATC细胞阻滞于G2/M期。
  • BRAF抑制与阿昔替尼联用在原位ATC模型中显著抑制肿瘤生长并与生存改善相关。

关键数值与推荐

  • 联用对细胞增殖的叠加效应依据Chou-Talalay算法判定。
  • 联用抑制细胞侵袭和迁移与对照相比p < 0.001。
  • BRAFV600E突变在ATC患者中占45%。

临床怎么用

  • 作者认为该联合可能对当前标准治疗即BRAF联合MEK抑制难治的BRAFV600E突变ATC有临床价值。

局限性

  • 原文未报告局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Background: Anaplastic thyroid cancer (ATC) is uniformly lethal. BRAFV600E mutation is present in 45% of patients with ATC. Targeted therapy with combined BRAF and MEK inhibition in BRAFV600E-mutant ATC can be effective, but acquired resistance is common because this combination targets the same pathway. Drug matrix screening, in BRAFV600E ATC cells, of highly active compounds in combination with BRAF inhibition showed multitargeting tyrosine kinase inhibitors (MTKIs) had the highest synergistic/additive activity. Thus, we hypothesized that the combination of BRAFV600E inhibition and an MTKI is more effective than a single drug or combined BRAF and MEK inhibition in BRAFV600E-mutant ATC. We evaluated the effect of BRAFV600E inhibitors in combination with the MTKI axitinib and its mechanism(s) of action. Methods: We evaluated the effects of BRAFV600E inhibitors and axitinib alone and in combination in in vitro and in vivo models of BRAFV600E-mutant and wild-type ATC. Results: The combination of axitinib and BRAFV600E inhibitors (dabrafenib and PLX4720) showed an additive effect on inhibiting cell proliferation based on the Chou-Talalay algorithm in BRAFV600E-mutant ATC cell lines. This combination also significantly inhibited cell invasion and migration (p < 0.001) compared with the control. Dabrafenib and PLX4720 arrested ATC cells in the G0/G1 phase. Axitinib arrested ATC cells in the G2/M phase by decreasing phosphorylation of aurora kinase B (Thr232) and histone H3 (Ser10) proteins and by upregulating the c-JUN signaling pathway. The combination of BRAF inhibition and axitinib significantly inhibited tumor growth and was associated with improved survival in an orthotopic ATC model. Conclusions: The novel combination of axitinib and BRAFV600E inhibition enhanced anticancer activity in in vitro and in vivo models of BRAFV600E-mutant ATC. This combination may have clinical utility in BRAFV600E-mutant ATC that is refractory to current standard therapy, namely combined BRAF and MEK inhibition.

来源:Thyroid,查看原文。版权归原作者所有。

引用

  1. Gunda V, Ghosh C, Hu J, et al. Combination BRAFV600E Inhibition with the Multitargeting Tyrosine Kinase Inhibitor Axitinib Shows Additive Anticancer Activity in BRAFV600E-Mutant Anaplastic Thyroid Cancer. Thyroid. 2023. PMID: 37675898. doi:10.1089/thy.2023.0201

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。